A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) over a longer time.
Participants of the following previous mezagitamab studies will be invited to join this continuation study: TAK-079-3002 and TAK-079-1004. In this continuation study, participants will receive mezagitamab when certain protocol criteria are met.
During the study, participants will visit their study clinic several times.
Key Inclusion Criteria:
1. The participant has completed TAK-079-3002 (end of trial [EOT]) or TAK-079-1004 (EOT). Participants from TAK-079-1004 must have had a response to mezagitamab as demonstrated by meeting the criteria for "platelet response" specified for that trial during either the main study or open-label extension.
Key Exclusion criteria:
For TAK-079-3002 participants:
1. The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation.
For TAK-079-1004 participants:
The participant has had any thrombotic or embolic event within 12 months before signing the ICF.
The participant has had a splenectomy within 3 months before signing the ICF.
The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for treated non-melanoma skin cancer or cervical carcinoma in situ.
In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
The participant has received anti-cluster of differentiation (CD) 20 treatment within 12 months before screening and either of the following applies:
The participant has received any monoclonal or polyclonal antibody for immunomodulation within 6 months before Visit 1.
The participant has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.
The participant has used anticoagulants (for example, vitamin K antagonists, direct oral anticoagulants) within 3 weeks prior to Visit 1.
10 The participant has received a live or live-attenuated vaccine within 4 weeks prior to the first dose of trial treatment or has any live or live-attenuated vaccine planned during the trial.
11. The participant has used the following immunosuppressive agents as specified prior to Visit 1: alkylating agents (for example, cyclophosphamide) within 8 weeks, vinca alkaloids (for example, vincristine) within 4 weeks, sulfones (for example, dapsone) within 3 weeks, antiproliferative agents: (for example, mycophenolate mofetil and azathioprine) within 2 weeks, and calcineurin inhibitors: (for example, cyclosporine) within 2 weeks.
12. The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation.
Other protocol defined inclusion/exclusion criteria may apply.
medinfoUS@takeda.com+1-877-825-3327
Hot Springs, Arkansas 71913, United States
Los Angeles, California 90033, United States
Washington D.C., District of Columbia 20007, United States
Louisville, Kentucky 40202, United States
Worcester, Massachusetts 01655, United States
Morristown, New Jersey 07960, United States
Philadelphia, Pennsylvania 19104, United States
Philadelphia, Pennsylvania 19140, United States
Liverpool, New South Wales 2170, Australia
Melbourne, Victoria 3004, Australia
Sofia, Sofia-Grad 1606, Bulgaria
Stara Zagora, 6003, Bulgaria
Wuhan, Hebei 430022, China
dr_huyu@126.com+8613986183871
Suzhou, Jiangsu 215006, China
Nanchang, Jiangxi 330006, China
Shenyang, Liaoning 110004, China
Tianjin, Tianjin Municipality 300020, China
Hangzhou, Zhejiang 310006, China
Rome, Lazio oo610, Italy
Catania, Sicily 95122, Italy
Bologna, 40123, Italy
Milan, 20162, Italy
Chuo-ku, Chiba 260-0852, Japan
Narashino-shi, Chiba 275-8580, Japan
choryuko@gmail.com047-473-1281
Hirakata-shi, Osaka 573-1191, Japan
tot@hirakata.kmu.ac.jp
Suita-shi, Osaka 565-0871, Japan
Iruma-gun, Saitama 350-0495, Japan
Bunkyo-ku, Tokyo 113-8655, Japan
kurokawa@m.u-tokyo.ac.jp03-3815-5411
Itabashi-ku, Tokyo 173-8610, Japan
ootake.shimon@nihon-u.ac.jp03-3972-8111
Sumida-ku, Tokyo 130-0022, Japan
Rotterdam, South Holland 3015 GD, Netherlands
Warsaw, Masovian Voivodeship 02-776, Poland
Mamak, Ankara 6620, Turkey (Türkiye)
Efeler, Aydın 9100, Turkey (Türkiye)
dryavas09@gmail.com
Sakarya, 54290, Turkey (Türkiye)
Leicester, East Midlands LE1 5WW, United Kingdom
Southwark, London DE1 9RT, United Kingdom
Liverpool, Merseyside L7 8XP, United Kingdom
Stoke-on-Trent, Staffordshire ST4 6QG, United Kingdom
phil.choi@act.gov.au+61251248492
vivien.chen@health.nsw.gov.au+610297676348
amanda.hugman@health.nsw.gov.au+61 02 9113 3089
Jennifer.curnow@health.nsw.gov.au+610288905200
ross@pbi.org.au+61892005300
viktoriia1982@abv.bg(359) 884-6741 x60
kasapunarova@yahoo.com+359887860806
dr.alaikov@gmail.com+359888627955
zhutn@pumch.cn+861069155027
lcw0589@163.com+8613437843806
jhlee3@amc.seoul.kr+867715356566
liuqingchi@sina.com+8631185917000
tigerzhoupumc@163.com+8637165587320
yinjie@suda.edu.cn+8613651003886
rbhuang69@163.com+867918692517
+8618940259833
houming@medmail.com.cn+8653182169114-9879
ypark@augusta.edu+862164041990Ext.2718
huaxigcp@163.com+862885422366
chenyunfei@ihcams.ac.cn+8613502157159
zhouzeping@kmmu.edu.cn+8618788571605
13588453501@163.com+8613588453501
fabrizio.pane@unina.it+39 081 7464289
uconsoli@arnasgaribaldi.it+39 095 7595801
andrea.patriarca@uniupo.it39 0321 3733092
g.carli@aulss8.veneto.it
takuya_m@yokohama-cu.ac.jp045-261-5656
81 6-6245-2117
055-253-7111
Yoshida.chikashi.rc@mail.hosp.go.jp029-240-7711
crisizquierdo3@yahoo.es+34 915868443 / +34 915868120
denis.zafra@salud.madrid.org+34 917792876
mariae.mingot.sspa@juntadeandalucia.es+34 628377490
sktoprak@yahoo.com905327000000
mdemir@trakya.edu.tr905336000000
mamta.garg@uhl-tr.nhs.uk
syed.kazmi@utsouthwestern.edu
m.scully@nhs.net442034479984